Payment overview · 2025
General Payments
$894.79
54 reported records · 13 companies
Healthcare provider profile · identity verified
Ahsen Ali Butt, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · PIKEVILLE, KY · NPI 1528001633
Verified facts
What the public records show
CMS Open Payments records show Ahsen Ali Butt, M.D. received $894.79 in general payments during 2025 across 54 reported records.
ABBVIE INC. accounted for 16.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Linzess, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $145.11 | 16.2% | 9 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $135.23 | 15.1% | 15 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $125.66 | 14.0% | 5 | 2025 |
| Travere Therapeutics, Inc. | Unresolved — no canonical attribution shown | $82.43 | 9.2% | 5 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $77.18 | 8.6% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $75.39 | 8.4% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $54.56 | 6.1% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $52.43 | 5.9% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $38.93 | 4.3% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.66 | 4.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $36.51 | 4.1% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.15 | 2.2% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $14.55 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $894.79 | 54 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $129.12 | 14 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $125.66 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $112.74 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $112.05 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $102.74 | 5 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $77.18 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $52.43 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $52.43 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $38.93 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $32.37 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $32.37 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $24.43 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $21.28 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $21.28 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $21.28 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $20.15 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $19.39 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.35 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $18.16 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $14.55 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.89 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $13.89 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $6.11 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 78 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 93 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 40 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 39 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 108 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
40 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
78 | 20 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
93 | 20 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
108 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
93 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
39 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
48 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 442 | 123 |
| Lisinopril | Lisinopril | 401 | 96 |
| Pantoprazole Sodium | Pantoprazole Sodium | 359 | 106 |
| Amlodipine Besylate | Amlodipine Besylate | 340 | 96 |
| Atorvastatin Calcium | Atorvastatin Calcium | 340 | 101 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 262 | 72 |
| Metoprolol Succinate | Metoprolol Succinate | 200 | 54 |
| Tamsulosin Hcl | Tamsulosin Hcl | 198 | 49 |
| Trazodone Hcl | Trazodone Hcl | 179 | 50 |
| Furosemide | Furosemide | 165 | 52 |
| Losartan Potassium | Losartan Potassium | 164 | 53 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 160 | 57 |
| Carvedilol | Carvedilol | 158 | 42 |
| Meloxicam | Meloxicam | 156 | 48 |
| Omeprazole | Omeprazole | 147 | 48 |
| Metformin Hcl | Metformin Hcl | 134 | 48 |
| Montelukast Sodium | Montelukast Sodium | 134 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 133 | 36 |
| Ezetimibe | Ezetimibe | 133 | 39 |
| Potassium Chloride | Potassium Chloride | 133 | 32 |
| Glipizide | Glipizide | 131 | 36 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 128 | 40 |
| Simvastatin | Simvastatin | 124 | 38 |
| Buspirone Hcl | Buspirone Hcl | 113 | 31 |
| Ropinirole Hcl | Ropinirole Hcl | 110 | 34 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 108 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 106 | 25 |
| Fenofibrate | Fenofibrate Nanocrystallized | 101 | 33 |
| Allopurinol | Allopurinol | 100 | 24 |
| Sertraline Hcl | Sertraline Hcl | 99 | 23 |
| Ibuprofen | Ibuprofen | 95 | 33 |
| Jardiance | Empagliflozin | 93 | 20 |
| Prednisone | Prednisone | 93 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 91 | 25 |
| Gabapentin | Gabapentin | 90 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 86 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 84 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 81 | 31 |
| Farxiga | Dapagliflozin Propanediol | 78 | 20 |
| Januvia | Sitagliptin Phosphate | 77 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 74 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 67 | 18 |
| Alendronate Sodium | Alendronate Sodium | 65 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 62 | 14 |
| Famotidine | Famotidine | 61 | 20 |
| Clonidine Hcl | Clonidine Hcl | 57 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 54 | 14 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 54 | 15 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 52 | 17 |
| Warfarin Sodium | Warfarin Sodium | 49 | suppressed |
| Eliquis | Apixaban | 48 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 47 | 29 |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 47 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 47 | suppressed |
| Ondansetron Odt | Ondansetron | 45 | 21 |
| Ventolin Hfa | Albuterol Sulfate | 45 | 23 |
| Entresto | Sacubitril/Valsartan | 44 | 12 |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 44 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 42 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 42 | 16 |
| Levetiracetam | Levetiracetam | 41 | 11 |
| Linzess | Linaclotide | 40 | 11 |
| Bupropion Xl | Bupropion Hcl | 39 | 11 |
| Ozempic | Semaglutide | 39 | 11 |
| Spironolactone | Spironolactone | 39 | 13 |
| Mounjaro | Tirzepatide | 38 | suppressed |
| Xarelto | Rivaroxaban | 38 | suppressed |
| Methylprednisolone | Methylprednisolone | 36 | 27 |
| Nitroglycerin | Nitroglycerin | 35 | 14 |
| Aripiprazole | Aripiprazole | 34 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | suppressed |
| Atenolol | Atenolol | 33 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 33 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | suppressed |
| Pregabalin | Pregabalin | 31 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 30 | 12 |
| Trulicity | Dulaglutide | 30 | suppressed |
| Celecoxib | Celecoxib | 29 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 29 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 29 | suppressed |
| Topiramate | Topiramate | 29 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Sucralfate | Sucralfate | 28 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Ranolazine Er | Ranolazine | 27 | suppressed |
| Cephalexin | Cephalexin | 26 | 24 |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 26 | suppressed |
| Nystatin | Nystatin | 25 | 14 |
| Sotalol | Sotalol Hcl | 23 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Clonazepam | Clonazepam | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | 15 |
| Levofloxacin | Levofloxacin | 21 | 20 |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 19 |
| Theophylline Er | Theophylline Anhydrous | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 19 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 16 |
| Bumetanide | Bumetanide | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 16 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 16 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 15 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Azithromycin | Azithromycin | 13 | 12 |
| Novolog | Insulin Aspart | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $894.79 · 54 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, AREXVY, Auvelity, COMIRNATY, CREON, Dexcom G6 Transmitter, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, Korlym, LINZESS, NURTEC ODT, Ozempic, PAXLOVID, PREVNAR 20, Prolastin-C Liquid, QULIPTA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VYNDAQEL | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error